Loading
Rocket Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Jan 2026.
Rocket Pharmaceuticals, Inc.: what insiders have been doing
Headquartered in Cranbury, United States, Rocket Pharmaceuticals, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 48 filings signed by 20 insiders.
Open-market activity splits into 1 purchase totalling €29k and 20 sales totalling €527k; 1 insider sit on the buying side and 6 insiders on the selling side. On balance, insiders were net sellers of €498k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 senior executive among the declarants. Biggest ticket of the year: €221k, sold by Wilson Martin and made public on 15 September 2026 (0.076% of market cap).
The last purchase on record was published on 6 January 2026, which is 285 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 48 filings here. Our records for Rocket Pharmaceuticals, Inc. go back to 2021, with 6 purchases and 86 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -223.1 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
178
Thresholds
n/a
Buy Volume
€21M
6 ops. · all time
Sell Volume
€37M
86 ops. · all time
Who traded when
BuySaleMartin Wilson13 sales
Militello John13 sales
Gaurav Shah1 buy10 sales
Patel Kinnari1 buy4 sales
Schwartz Jonathan David5 sales
Bjork Elisabeth2 buys
+3 other insiders
Since the insiders bought
- -10.5%Entry US$3.89 · Close at T+90 US$3.48
- -40.6%Entry US$6.53 · Close at T+365 US$3.88
- -30.9%Entry US$5.27 · Close at T+365 US$3.64
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Rocket Pharmaceuticals, Inc. Buy (bullish), based on 12 analysts. Average price target: US$8.58.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.21
Analyst consensus
12 analystsBuy
US$2.95Target US$8.58(+288%)US$15.00
Income statement
EBITDA-US$210.2M
Net income-US$223.1M0.0% margin
Valuation
PER (forward)-1.7x
P/Book0.7x
Beta0.50
Balance sheet & cash
Market capUS$242.6M
Total debtUS$24.9M
Free Cash Flow-US$190.5M
Debt / Equity7%
Profitability & ownership
ROE-4.8%
ROA-28.4%
% insiders3.2%
% institutions91.8%
Last declaration on 15 September 2026
Declarations178 total
6,897 shares@ US$3.29570.0068% mcap3.0% of flowCommonSEC144:0001959173-26-006989
75,364 shares@ US$3.4030.076% mcap26.4% of flowCommon StockSEC:0001140361-26-036688:0
6,857 shares@ US$3.3150.0067% mcap3.0% of flowCommonSEC144:0001959173-26-006938
8,923 shares@ US$3.40330.0090% mcap4.0% of flowCommonSEC144:0001959173-26-006907
75,364 shares@ US$3.40330.076% mcap26.4% of flowCommonSEC144:0001959173-26-006908
2,293 shares@ US$3.3810.0023% mcap0.3% of flowCommon StockSEC:0001140361-26-033913:0
631 shares@ US$3.3810.0006% mcap0.2% of flowCommon StockSEC:0001140361-26-033915:0
1,252 shares@ US$3.38140.0013% mcap0.6% of flowCommonSEC144:0001959173-26-006166
631 shares@ US$3.38140.0006% mcap0.2% of flowCommonSEC144:0001959173-26-006168
2,293 shares@ US$3.38140.0023% mcap0.3% of flowCommonSEC144:0001959173-26-006169
3,493 shares@ US$3.3810.0035% mcap1.2% of flowCommon StockSEC:0001140361-26-033413:0
2,837 shares@ US$3.3810.0029% mcap0.4% of flowCommon StockSEC:0001140361-26-033417:0
3,493 shares@ US$3.38110.0035% mcap1.2% of flowCommonSEC144:0001959173-26-005995
2,837 shares@ US$3.38110.0029% mcap0.4% of flowCommonSEC144:0001959173-26-005994
4,701 shares@ US$3.4990.0049% mcap50.0% of flowCommon StockSEC:0001140361-26-032816:0
36,658 shares@ US$3.4990.038% mcap50.0% of flowCommon StockSEC:0001140361-26-032818:0
4,701 shares@ US$3.49940.0049% mcap50.0% of flowCommonSEC144:0001959173-26-005891
36,658 shares@ US$3.49940.038% mcap50.0% of flowCommonSEC144:0001959173-26-005892
150,000 shares0Common StockSEC:0001140361-26-031471:0
73,313 shares0Common StockSEC:0001140361-26-031473:0
10,670 shares@ US$3.87940.012% mcap100.0% of flowCommonSEC144:0001959173-26-005144
22,862 shares0Common StockSEC:0001140361-26-027676:0
27,832 shares0Common StockSEC:0001140361-26-027681:0
22,862 shares0Common StockSEC:0001140361-26-027680:0
22,862 shares0Common StockSEC:0001140361-26-027678:0
25 of 178 declarations
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is a U.S.-based biotechnology company listed on the NASDAQ under the ticker RCKT. For European investors, it fits the profile of a specialty biopharma company focused on rare, severe, and often life-threatening diseases, where value creation is driven primarily by clinical data, regulatory milestones, and, increasingly, commercialization rather than by broad commercial penetration.
Founded in 1999, Rocket has spent years building an integrated gene-therapy platform that spans discovery, clinical development, and manufacturing capabilities. The company’s core R&D and corporate headquarters are in Cranbury, New Jersey, with an additional corporate presence in New York. Rocket describes itself as a fully integrated biotechnology company, and in 2026 it crossed an important threshold by securing accelerated approval for KRESLADI™ in severe leukocyte adhesion deficiency-I (LAD-I). That approval gives the group its first marketed product, but the investment case is still dominated by the strength, breadth, and execution risk of the pipeline.
Read moreShow less
Rocket’s competitive positioning rests on disease-modifying gene therapies designed to address the underlying genetic defect, not just symptoms. The company’s most important programs are concentrated in cardiovascular genetics and rare hematology/immunology. In cardiovascular disease, the key assets include RP-A501 for Danon disease, RP-A601 for PKP2-associated arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-associated dilated cardiomyopathy. In hematology/immunology, KRESLADI targets severe LAD-I, while the company also has legacy and earlier-stage programs in Fanconi anemia and pyruvate kinase deficiency. This focused pipeline gives Rocket several shots on goal, but it also leaves the investment thesis exposed to small patient populations, complex trial design, manufacturing demands, and regulatory uncertainty.
From an industry standpoint, Rocket is competing in the high-science rare-disease gene-therapy arena, where credibility in clinical execution and CMC quality is crucial. The company has benefited from various regulatory designations over time, which can support development speed but do not eliminate risk. Recent highlights through 2025 and 2026 include the FDA lifting the clinical hold on the pivotal RP-A501 Danon study, the resumption of dosing, the FDA acceptance and subsequent approval path for KRESLADI, and the monetization of a Rare Pediatric Disease Priority Review Voucher for $180 million, which improved liquidity and reduced near-term financing pressure. Overall, Rocket Pharmaceuticals remains a high-beta rare-disease biotech with meaningful upside optionality, but also substantial dependence on execution across a concentrated pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
